PACE-CME

Challenges in targeting residual risk in diabetic patients, post ACS

Challenges in targeting residual risk in diabetic patients post ACS
RestartResume
10' education - Sep. 25, 2019 - Prof. Peter Libby, MD
  • Overview

    Prof. Libby discusses the inflammatory residual risk in diabetes patients and explains how epigenetic modulation of (inflammatory) gene transcription can potentially reduce CV risk.

  • Educational information

    This lecture by prof. Peter Libby was part of an accredited symposium "Epigenetics: A new pathway to tackle residual risk?" held during ESC 2019 in Paris, France.

  • Faculty

    Peter Libby, MD is a cardiologist and a cardiovascular medicine specialist at Brigham and Women’s Hospital (Boston, MA, USA) and the Mallinckrodt Professor of Medicine at Harvard Medical School (Boston, MA, USA).

  • Disclosures

    This recording was independently developed under auspices of PACE-cme. The views expressed in this recording are those of the individual presenter and do not necessarily reflect the views of PACE-cme.

  • Funding

    Funding for this educational program was provided by an unrestricted educational grant from Resverlogix.

    The content is aimed for medical professionals. To view this item member registration is needed. Register for free to get unlimited access to our educational resources.
    The information and data provided in this program were updated and correct at the time of the program development, but may be subject to change.

Facebook Comments

Register

We’re glad to see you’re enjoying PACE-CME…
but how about a more personalized experience?

Register for free